MMIT (Managed Markets Insight & Technology)

Ready to dive into #MarketAccess planning for your medical benefit drug? Our primer is your practical guide, leading you through every step, from predicting uptake and tracking policies/pathways to payer contracting and provider engagement. Download the ebook now to discover the five crucial steps your organization should take to establish a firm foundation for your commercialization journey: https://ow.ly/jyfB50SphTW. #MedicalBenefitTherapy #MedicalBenefitTherapies #CommercializationStrategy #HCPs

Larger manufacturers with greater funding and contracting power are entering the digital therapeutics market. In this blog, MMIT's CCO Jayne Hornung discusses the challenges and opportunities of prescription digital therapeutics: https://ow.ly/Rxok50QZ4K8 #DigitalTherapeutics #DTx #Pharma #PharmaceuticalCompanies #PrescriptionDigitalTherapeutics #PTD

The oncology space is no longer subject to minimal payer management. MMIT’s Jory Fleischauer discusses utilization management and the likely rise in competitive contracting coming to this therapeutic area. Read now: https://ow.ly/7X9S50Rlykx #OncologyTherapies #CancerCare #PayerManagement #Oncology

Now available in the new issue of Health Plan Weekly: How the Chevron ruling could bring chaos to health care rulemaking, appeals court backs Cigna Healthcare in noncompete dispute, why pharmacists want SCOTUS to weigh another PBM case, and more top stories. https://hubs.ly/Q02Fn1LG0

Meetings between pharma companies and managed care organizations increasingly prioritize financial over clinical discussions. MMIT's Jonathan Cecire and Norstella's Dinesh Kabaleeswaran cover communication trends. https://ow.ly/NlNN50SmHU5

With drug shortages in the U.S. at a two-decade high, MMIT’s Andrew Rouff discusses mitigation options, the proposed Medicare Drug Shortage Prevention and Mitigation Program, and how payers tend to respond to shortages. https://ow.ly/q3a050SrfAM

Healthcare stakeholders have serious concerns about the security of using AI tools with sensitive payer, physician and patient data. In the International Journal of Science and Research (IJSR), MMIT’s Iswarya Chandramouli and Dinesh Kannan Kabaleeswaran discuss research on how payers perceive their use of AI tools. https://ow.ly/6Acb50Sc73Q #ArtificialIntelligence #AITools #ChatGPT #PatientAccess #ClaimsData

Payers representing 90% of commercial lives say interchangeability plays a key role in the coverage decision for Humira biosimilars. MMIT’s Catherine Humphries and Julia Scanlan explore adoption and pricing factors in this blog. https://ow.ly/8nMY50QeUNY #HumiraBiosimilars #Pharma #Pharmaceuticals

Pharma companies often lack knowledge of the coverage landscape in drug categories dominated by low-cost generics. In this case study, we see how one women’s health pharmaceutical company used MMIT’s solutions to evaluate access for its brand and drive new prescriptions. https://ow.ly/h10g50Su6rG #Pharma #PharmaCompany #WomensHealth #MarketAccess

New in this week's Radar on Medicare Advantage: The 'wild and crazy' opening for Special Needs Plans, how MA orgs are supporting aging in place with new tech, the House bill that would cover obesity drugs for a small share of new Medicare enrollees, and more top stories. https://hubs.ly/Q02Ff_lB0